The DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial was the first study that evaluated the efficacy of an SGLT2 inhibitor in patients with HF with reduced ejection fraction (HFrEF) irrespective of T2DM.45 The trial enrolled 4,744 patients with stable, chronic HF with LVEF ≤ 40% who were followed over a period of 18 months. The gene discussed is SLC5A2; the disease is hydrops fetalis.